Notes for P&L
All amounts in SEKm unless otherwise stated
Note 19 Non-current finanical assets
| Parent Company | ||||||
|---|---|---|---|---|---|---|
| Receivables from Group companies | 2020-12-31 | 2019-12-31 | ||||
| Opening balance | 1,278.0 | 1,027.9 | ||||
| Increase during the year | 731.9 | 419.5 | ||||
| Decrease during the year | -300.7 | -169.4 | ||||
| Carrying amount at year-end | 1,709.2 | 1,278.0 | ||||
| Specification of interests in Group companies | Country | Number of shares | Quotient value | Holding % | Carrying amount 2020-12-31 | Carrying amount 2019-12-31 |
| AddLife Development AB | Sweden | 1,000 | 100 | 100% | 389.1 | 389.1 |
| Biomedica Holding GmbH | Austria | 37,500 | 1 | 0% | – | 416.5 |
| Interests in Group companies | Parent Company | |||||
| Accumulated cost | 2020 | 2019 | ||||
| Opening balance | 805.6 | 797.6 | ||||
| Acquisitions for the year | – | 8.0 | ||||
| Disposals for the year¹ | -416.5 | – | ||||
| Closing balance | 389.1 | 805.6 | ||||
| ¹ Internal sale of Biomedica Holding GmbH to AddLife Development AB | ||||||
| Indirect ownership | |||||||
|---|---|---|---|---|---|---|---|
| Indirect ownership | Ownership | Indirect ownership | Ownership | Indirect ownership | Ownership | ||
| Biomedica Medizinprodukte GmbH | 100% | Mediplast GmbH | 100% | Lab-Vent Controls A/S | 100% | ||
| Biomedica Services AG | 100% | Mediplast Holding Aps | 100% | Koldt & Ryø El A/S | 100% | ||
| Biomedica Medizintechnik AG | 100% | Mediplast A/S | 100% | Immuno Diagnostics Oy | 100% | ||
| Euromed Swiss AG | 100% | Hospidana A/S | 100% | Bergman Diagnostika AS | 100% | ||
| Biomedis d.o.o. | 100% | Fenno Medical Oy | 100% | BioNordika (Denmark) A/S | 100% | ||
| Biomedica MP d.o.o. | 100% | Svan Care AB | 100% | BioNordika Bergman AS | 100% | ||
| Biomedica Dijagnostika doo | 100% | Hepro AS | 100% | BioNordika (Sweden) AB | 100% | ||
| Biomedica d.o.o. | 100% | Esthe-Tech AB | 100% | BioNordika (Finland) Oy | 100% | ||
| Biomedica Bulgaria ood | 100% | V-tech AB | 100% | Funksjonsutstyr AS | 76% | ||
| Biomedica Medizinprodukte Romania SRL | 100% | Väinö Korpinen Oy | 100% | EuroClone S.p.A. | 100% | ||
| Biomedica Hungaria Kft. | 100% | Triolab Oy | 100% | TechniPro PulmoMed Pty Ltd | 100% | ||
| Biomedica CS s.r.o. | 100% | Triolab AB | 100% | Ropox A/S | 100% | ||
| Biomedica Poland Sp. Zo.o. | 100% | Triolab (Baltics) Oy | 100% | Dach Medical Group Holding AG | 100% | ||
| Biomedica Dijagnostika d.o.o.el | 100% | LabRobot Products AB | 100% | Dach Austria Medical Group GmbH | 100% | ||
| Biomedica Slovakita s.r.o. | 80% | BergmanLabora AB | 100% | Dach Switzerland Medical Group GmbH | 100% | ||
| Mediplast AB | 100% | Biolin Scientific AB | 100% | D-A-CH Germany Medical Group GmbH | 100% | ||
| Mediplast AS | 100% | Biolin Scientific China | 100% | Zafe Care Systems AB | 100% | ||
| Mediplast Sataside Oy | 100% | Biolin Scientific Oy | 100% | Biomedica Italia s.r.l | 100% | ||
| Mediplast S.r.l | 100% | Biolin Scientific LTD | 100% | ||||
| Mediplast Benelux B.V. | 100% | Holm & Halby A/S | 100% | ||||
Accounting principle
Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense. Shareholder contributions provided by the Parent Company are recognized in shares, when impairment is not required.
To the top